In a groundbreaking study, researchers from the Genome Institute of Singapore (GIS) developed a new computer model of machine learning (an artificial intelligence model, AI) to accurately find tumor mutations. They alsoRead More…
Most proteins have a tendency to form polymers, which are accompanied by slow polymer formation when they are produced, stored, transported, and injected into a patient. There are two reasons for whyRead More…
Monoclonal antibodies (mAbs) — preparations of a specific type of antibody designed to bind to a single target — have shown promise in the fight against cancer and autoimmune diseases. They alsoRead More…
Model of Factor VIII. © 3d ribbon/surface model of the human factor VIII after PDB 3CDZ. Ref.: Ngo JC, Huang M, Roth DA, Furie BC, Furie B (April 2008). DOI:10.1016/j.str.2008.03.001. Roche’s USRead More…
“Two new studies use new models to identify genetic targets and test promising treatments for adrenal cancer. One patient was treated with the immunotherapy pembrolizumab and now more than a year afterRead More…
Great Achievements Have Been Made in Cancer Drug Listing In 2006-2017, a total of 89 oncology therapies (NTDs) were approved by the Center for Drug Evaluation and Research (CDER). The Biologics EvaluationRead More…
After more than 30 years of accumulation, monoclonal antibody drugs have become well-deserved mainstream branches in the field of medicine from targets development to technologies improvement. From clinical research to commercialization strategies,Read More…
Evaluate Pharma, a well-known market research organization in the field of medicine, recently released the report “EP Vantage 2018 Preview”, in which it reviewed the new drug approval in 2017, and predictedRead More…
A new study recently calculated the development costs of 10 new anti-tumor drugs over the 10-year period between 2006 and 2015, and found that the median development time for these 10Read More…
“Brentuximab Vedotin (Antibody-drug conjugate, ADC)was approved by the FDA in 2011 as the first new therapeutic option for patients with Hodgkin lymphoma in more than 30 years. Currently, brentuximab vedotin and nivolumabRead More…